AKT1 and cancer: Nevertheless, the identification of an autoinhibitory intramolecular interface in Sgk3, analogous but not homologous to Akt, presents opportunities for the development of Sgk3-specific inhibitors that may have clinical value in the treatment of cancers in which Sgk3 signaling is observed to be upregulated.